The conversation around psychedelic medicine in the United States has taken another significant step forward. On 14 September 2026, the US Food and Drug Administration (FDA) held a four-hour public hearing dedicated to the potential future therapeutic use of psychedelic drugs…
Research into psilocybin continues to expand, with scientists investigating its effects far beyond the psychedelic experience for which it is best known. Now, a study published in Science on 3 September 2026 has reported a particularly interesting finding: in preclinical models, psilocybin…
Could hormones influence how women respond to psilocybin and other psychedelics? New research is drawing attention to an important but surprisingly underexplored area of psychedelic science: the role of female sex hormones. Interest in psilocybin research has grown enormously in…
The world of psychedelic research has taken another significant step forward. On 7th July 2026, Compass Pathways announced encouraging new data from its second ongoing Phase 3 clinical trial investigating COMP360, a proprietary synthetic formulation of psilocybin, as a treatment…
With temperatures climbing across the UK once again, many researchers are turning their attention to an often-overlooked factor that can significantly affect their projects: temperature control. While warmer weather may be great for spending time outdoors, it can create challenges…
Researchers have published the results of a new randomised clinical trial investigating whether psilocybin-assisted therapy could help people living with cocaine use disorder. The study, published in JAMA Network Open, adds to a growing body of research exploring the potential…
As life expectancy continues to rise, scientists are increasingly focused on a different question: how can we age well? While modern medicine has helped people live longer, age-related cognitive decline, memory loss and neurodegenerative conditions such as Alzheimer’s disease remain…
Researchers from the Karolinska Institute in Sweden have found that a single dose of psilocybin, combined with psychological support, produced rapid reductions in depressive symptoms in people living with major depressive disorder. Some participants reported improvements within just a few days, with benefits continuing for several months afterwards.
New research published in Nature Communications suggests a single dose of psilocybin may lead to lasting structural brain changes. Explore what this means for neuroplasticity and mental health.
Scientists have engineered a tobacco plant to produce five different psychedelic compounds at once — combining genes from plants, mushrooms, and even toads. It’s a breakthrough that could reshape how these compounds are produced, but it also raises bigger questions about where this technology is heading.
